HARVARD BIOSCIENCE INC — Director's Dealing 2013

Nov 5, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2013-11-01

Reporting Person: UVEGES GEORGE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-11-01	Common Stock	J	3646	—	Acquired	27955	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-01	Stock option (right to buy)	$3.03	J	7928	Acquired	2016-03-24	Common Stock, par value $0.01 per share (7928)	Direct
2013-11-01	Stock option (right to buy)	$3.01	J	1589	Acquired	2016-05-25	Common Stock, par value $0.01 per share (1589)	Direct
2013-11-01	Stock option (right to buy)	$3.71	J	1603	Acquired	2017-05-24	Common Stock, par value $0.01 per share (1603)	Direct
2013-11-01	Stock option (right to buy)	$3.41	J	1586	Acquired	2018-05-22	Common Stock, par value $0.01 per share (1586)	Direct
2013-11-01	Stock option (right to buy)	$2.28	J	5720	Acquired	2019-05-21	Common Stock, par value $0.01 per share (5720)	Direct
2013-11-01	Stock option (right to buy)	$2.59	J	5445	Acquired	2020-06-04	Common Stock, par value $0.01 per share (5445)	Direct
2013-11-01	Stock option (right to buy)	$4.04	J	5707	Acquired	2021-06-02	Common Stock, par value $0.01 per share (5707)	Direct
2013-11-01	Stock option (right to buy)	$2.56	J	5113	Acquired	2022-06-01	Common Stock, par value $0.01 per share (5113)	Direct
2013-11-01	Stock option (right to buy)	$3.64	J	3616	Acquired	2023-05-31	Common Stock, par value $0.01 per share (3616)	Direct

Footnotes

F1: These additional options and restricted stock units were acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and required in connection with the spin-off of Harvard Apparatus Regenerative Technology, Inc. by the Issuer. As part of such required adjustment relating to the spin-off, the exercise price of the options underlying these adjustment option grants was also reset to the exercise price of these adjustment grants to reflect the impact of the spin-off. The share amounts and exercise prices of the adjusted options and restricted stock units were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing award was maintained immediately following the spin-off. In addition to these adjustments, to maintain such intrinsic value, equity awards issued by Harvard Apparatus Regenerative Technology, Inc. were also granted to the Reporting Person.

F2: Includes (a) an adjusted deferred stock award of 7,777 restricted stock units which shall fully vest on May 31, 2014; and (b) an adjusted deferred stock award of 7,377 restricted stock units which vest in equal installments on June 1, 2014 and June 1, 2015; and (c) 12,801 shares of common stock held by the Reporting Person.

F3: The option shares vested in three equal installments on March 24, 2007, 2008 and 2009.

F4: The option shares vested in three equal installments on May 25, 2007, 2008 and 2009.

F5: The option shares vested in three equal installments on May 24, 2008, 2009 and 2010.

F6: The option shares vested in three equal installments on May 22, 2009, 2010 and 2011.

F7: The option shares vested in three equal installments on May 21, 2010, 2011 and 2012.

F8: The option shares vested in three equal installments on June 4, 2011, 2012 and 2013.

F9: The option shares vest in three equal installments on June 2, 2012, 2013 and 2014.

F10: The option shares vest in three equal installments on June 1, 2013, 2014 and 2015.

F11: The options shall fully vest on May 31, 2014.